{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:49:27Z","timestamp":1792014567309,"version":"4.4.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Government Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ctrv.2026.103218","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:11:59Z","timestamp":1790809919000},"page":"103218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advancing therapies for HER2-positive metastatic breast cancer: Navigating a wealth of treatment options"],"prefix":"10.1016","volume":"150","author":[{"given":"Michela","family":"Palleschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Viansone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Merloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Farolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Miserocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Di Menna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Sabbioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Montanari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Sirico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mannozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Tegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cecconetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta","family":"Sarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103218_bb0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2026.103218_bb0010","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103218_bb0015","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103218_bb0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","article-title":"Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases: final overall survival analysis of HER2CLIMB","volume":"33","author":"Curigliano","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0030","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103218_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102664","article-title":"HER2 intratumoral heterogeneity in breast cancer, an evolving concept","volume":"15","author":"Hou","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103218_bb0040","article-title":"HER2 heterogeneity in breast cancer: biological basis, clinical implications, and therapeutic strategies","volume":"18","author":"Shi","year":"2026","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.ctrv.2026.103218_bb0045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103218_bb0050","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cortes","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103218_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open."},{"key":"10.1016\/j.ctrv.2026.103218_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102853","article-title":"Expert recommendations on treatment sequencing and challenging clinical scenarios in HER2-positive metastatic breast cancer","volume":"132","author":"Bartsch","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"4 Suppl","key":"10.1016\/j.ctrv.2026.103218_bb0065","article-title":"Trastuzumab deruxtecan plus pertuzumab versus taxane plus trastuzumab plus pertuzumab for first-line treatment of patients with HER2-positive advanced\/metastatic breast cancer: patient-reported outcomes from DESTINY-Breast09 [abstract]","volume":"32","author":"Rimawi","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103218_bb0070","unstructured":"Park YH, et al. 2026 ASCO annual meeting; abstract 1021."},{"key":"10.1016\/j.ctrv.2026.103218_bb0075","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2026.0033","article-title":"Breast cancer, version 4.2026, NCCN clinical practice guidelines in oncology","volume":"24","author":"Gradishar","year":"2026","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2026.103218_bb0080","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1200\/JCO.2017.76.7863","article-title":"First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer: the PERTAIN randomised phase II trial","volume":"36","author":"Rimawi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0085","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa2511218","article-title":"Palbociclib for hormone-receptor-positive, HER2-positive advanced breast cancer","volume":"394","author":"Metzger","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103218_bb0090","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1200\/JCO-25-02600","article-title":"HER2CLIMB-05: a phase III study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as first-line maintenance therapy for HER2-positive metastatic breast cancer","volume":"44","author":"Dieras","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0095","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.annonc.2021.06.024","article-title":"Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejca.2021.03.047","article-title":"Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer: the randomised phase II PHranceSCa study","volume":"152","author":"O\u2019Shaughnessy","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103218_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007667","article-title":"Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016)","volume":"11","author":"Pellegrino","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103218_bb0110","unstructured":"DEMETHER trial. ClinicalTrials.gov identifier: NCT06172127."},{"key":"10.1016\/j.ctrv.2026.103218_bb0115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41571-023-00849-9","article-title":"Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives","volume":"21","author":"Marra","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102761","article-title":"The evolving landscape of metastatic HER2-positive, hormone receptor-positive breast cancer","volume":"128","author":"Boscolo Bielo","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2026.103218_bb0125","article-title":"Emerging treatments in HER2-positive advanced breast cancer: keep raising the bar","volume":"5","author":"Agostinetto","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ctrv.2026.103218_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101613","article-title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis","volume":"8","author":"Soares","year":"2023","journal-title":"ESMO Open."},{"key":"10.1016\/j.ctrv.2026.103218_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102043","article-title":"Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan-induced interstitial lung disease in breast cancer patients","volume":"8","author":"Wekking","year":"2023","journal-title":"ESMO Open."},{"key":"10.1016\/j.ctrv.2026.103218_bb0140","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10549-024-07431-6","article-title":"Receptor discordance in metastatic breast cancer: a review of clinical and genetic subtype alterations from primary to metastatic disease","volume":"207","author":"Dowling","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2026.103218_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105016","article-title":"Prognostic value of HER2 discordance between primary and metastatic or recurrent breast cancer: a systematic review and meta-analysis","volume":"217","author":"Nakatani","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0150","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-025-00753-8","article-title":"HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab","volume":"11","author":"Sanchez-Bayona","year":"2025","journal-title":"NPJ Breast Cancer."},{"key":"10.1016\/j.ctrv.2026.103218_bb0155","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-026-00909-0","article-title":"Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane","volume":"12","author":"Kubeczko","year":"2026","journal-title":"NPJ Breast Cancer."},{"key":"10.1016\/j.ctrv.2026.103218_bb0160","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.clon.2023.08.006","article-title":"Ten-year outcomes of stereotactic body radiotherapy for oligometastatic breast cancer: does synchronous oligometastatic breast cancer benefit?","volume":"35","author":"Nagpal","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ctrv.2026.103218_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110240","article-title":"Definitive results of a prospective non-randomised phase II study on stereotactic body radiation therapy for medically inoperable lung and liver oligometastases from breast cancer","volume":"195","author":"Franceschini","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0170","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10585-024-10312-3","article-title":"Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives","volume":"41","author":"Merloni","year":"2024","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ctrv.2026.103218_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70268","article-title":"The safety of trastuzumab deruxtecan in breast cancer brain metastases with a focus on interstitial lung disease\/pneumonitis: a systematic review and meta-analysis","volume":"132","author":"Ma","year":"2026","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103218_bb0180","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.22.00520","article-title":"Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update","volume":"40","author":"Ramakrishna","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0185","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0190","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1200\/JCO.22.00333","article-title":"Radiation therapy for brain metastases: ASCO guideline endorsement of ASTRO guideline","volume":"40","author":"Schiff","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0195","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103218_bb0200","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102924","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomised DESTINY-Breast03 trial","volume":"9","author":"Hurvitz","year":"2024","journal-title":"ESMO Open."},{"key":"10.1016\/j.ctrv.2026.103218_bb0210","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.annonc.2024.08.2347","article-title":"A pooled analysis of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer with brain metastases","volume":"35","author":"Andre","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0215","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103218_bb0220","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/neuonc\/noae123","article-title":"Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab deruxtecan in HER2-positive breast cancer patients with active brain metastases","volume":"26","author":"Bartsch","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0225","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/neuonc\/noac144","article-title":"Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial","volume":"25","author":"Perez-Garcia","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0230","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103218_bb0235","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1078-0432.CCR-22-1138","article-title":"Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases","volume":"29","author":"Kabraji","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103218_bb0240","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s12282-024-01614-1","article-title":"Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and\/or leptomeningeal metastases: updated overall survival analysis from ROSET-BM","volume":"31","author":"Nakayama","year":"2024","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103218_bb0245","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s43018-026-01120-7","article-title":"Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2-positive breast cancer: TBCRC049 phase II study results","volume":"7","author":"Murthy","year":"2026","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ctrv.2026.103218_bb0250","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andre","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103218_bb0255","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1158\/2159-8290.CD-25-0647","article-title":"Trastuzumab deruxtecan resistance via loss of HER2 expression and binding","volume":"16","author":"Chen","year":"2026","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2026.103218_bb0305","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.4435","article-title":"Tucatinib combination treatment after trastuzumab deruxtecan in patients with ERBB2-positive metastatic breast cancer","volume":"7","author":"Frenel","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ctrv.2026.103218_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105511","article-title":"Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study","volume":"10","author":"Nozawa","year":"2025","journal-title":"ESMO Open."},{"key":"10.1016\/j.ctrv.2026.103218_bb0265","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10549-025-07853-w","article-title":"Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer","volume":"215","author":"Zelizer","year":"2026","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2026.103218_bb0270","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/jnci\/djaf220","article-title":"Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer","volume":"117","author":"Tarantino","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2026.103218_bb0275","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer: final overall survival results from TH3RESA","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0280","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO-24-01673","article-title":"Pertuzumab retreatment for HER2-positive locally advanced\/metastatic breast cancer: final overall survival analysis of the PRECIOUS study","volume":"43","author":"Yamamoto","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0285","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1200\/JCO.21.02937","article-title":"Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer: final overall survival results from the randomised phase III SOPHIA trial","volume":"41","author":"Rugo","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0290","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with at least two HER2-directed regimens: the phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0295","first-page":"11","article-title":"Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing","volume":"8","author":"Larose","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.ctrv.2026.103218_bb0300","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1158\/1078-0432.CCR-25-3321","article-title":"Payload diversification overcomes resistance and guides sequential antibody-drug conjugate therapy in breast cancer","volume":"32","author":"Rampa","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103218_bb0310","unstructured":"SATEEN trial. ClinicalTrials.gov identifier: NCT06100874."},{"key":"10.1016\/j.ctrv.2026.103218_bb0315","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-806","article-title":"Long-term tumour remission under trastuzumab treatment for HER2-positive metastatic breast cancer: results from the HER-OS patient registry","volume":"14","author":"Witzel","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103218_bb0320","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.breast.2015.09.008","article-title":"Long-term outcome of HER2-positive metastatic breast cancer patients treated with first-line trastuzumab","volume":"24","author":"Yeo","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2026.103218_bb0325","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10549-019-05423-5","article-title":"Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the French real-life curie database","volume":"178","author":"Kaczmarek","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2026.103218_bb0330","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-022-06718-w","article-title":"Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions","volume":"196","author":"Smith","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2026.103218_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104583","article-title":"Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study","volume":"84","author":"Ding","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2026.103218_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17213532","article-title":"Real-world evidence of long-term disease control in HER2-positive metastatic breast cancer patients treated with a first-line combination of trastuzumab and\/or pertuzumab plus chemotherapy","volume":"17","author":"Chaigneau","year":"2025","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ctrv.2026.103218_bb0345","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.22.00519","article-title":"Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update","volume":"40","author":"Giordano","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115321","article-title":"Exceptional responses to systemic treatment in metastatic breast cancer: clinical features and long-term outcomes","volume":"219","author":"Griguolo","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103218_bb0355","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10549-019-05427-1","article-title":"Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?","volume":"178","author":"Steenbruggen","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2026.103218_bb0360","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41523-024-00713-8","article-title":"Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer","volume":"10","author":"Cucciniello","year":"2024","journal-title":"NPJ Breast Cancer."},{"key":"10.1016\/j.ctrv.2026.103218_bb0365","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000202","article-title":"Retrospective analysis of HER2 therapy interruption in patients responding to treatment in metastatic HER2-positive breast cancer","volume":"2","author":"Moilanen","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103218_bb0370","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3747\/co.23.2743","article-title":"Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission","volume":"23","author":"Haq","year":"2016","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0375","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s12282-021-01240-1","article-title":"Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report","volume":"28","author":"Nagasaki","year":"2021","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103218_bb0380","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12282-023-01436-7","article-title":"Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1)","volume":"30","author":"Imoto","year":"2023","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103218_bb0385","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4143\/crt.2025.1131","article-title":"Toward sustainable care in HER2-positive metastatic breast cancer: emerging evidence for treatment de-escalation","volume":"58","author":"Lee","year":"2026","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2026.103218_bb0390","unstructured":"HEROES Clinical Trial (NCT06450314)."},{"key":"10.1016\/j.ctrv.2026.103218_bb0395","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003171","article-title":"Role of Fcgamma receptors in HER2-targeted breast cancer therapy","volume":"10","author":"Musolino","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103218_bb0400","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1200\/JCO.2007.14.8957","article-title":"Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2\/neu-positive metastatic breast cancer","volume":"26","author":"Musolino","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0405","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated HER2-positive advanced breast cancer: KATE2","volume":"21","author":"Emens","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0410","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","article-title":"Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer","volume":"30","author":"Hamilton","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103218_bb0415","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","article-title":"Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment","volume":"25","author":"Zippelius","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2026.103218_bb0420","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41571-024-00939-2","article-title":"Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance","volume":"21","author":"Waks","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0425","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for HER2-positive advanced breast cancer: primary results from the phase III MARIANNE study","volume":"35","author":"Perez","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0430","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.annonc.2025.11.005","article-title":"Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02","volume":"37","author":"Hurvitz","year":"2026","journal-title":"Ann Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.ctrv.2026.103218_bb0435","article-title":"Trastuzumab deruxtecan plus durvalumab in patients with previously untreated HER2-positive unresectable\/metastatic breast cancer: final analysis from DESTINY-Breast07 [abstract]","volume":"44","author":"Loi","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0440","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.24.00529","article-title":"Trastuzumab duocarmazine in pretreated HER2-positive advanced or metastatic breast cancer: an open-label, randomized, phase III trial (TULIP)","volume":"43","author":"Turner","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0445","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1158\/1078-0432.CCR-22-0456","article-title":"Phase I trial of a novel anti-HER2 antibody-drug conjugate, ARX788, for the treatment of HER2-positive metastatic breast cancer","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103218_bb0450","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/cac2.12577","article-title":"Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I\/Ib study","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.ctrv.2026.103218_bb0455","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0460","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1470-2045(25)00140-8","article-title":"Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study","volume":"26","author":"Escriva-de-Romani","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0465","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S1470-2045(26)00193-2","article-title":"Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"27","author":"Yao","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0470","doi-asserted-by":"crossref","unstructured":"Hu X, Yu J, Sun T, et al. Efficacy and safety of DP303c versus T-DM1 in HER2-positive advanced breast cancer: interim analysis of a randomized, open-label, phase 3 trial [abstract]. Clin Cancer Res 2026;32(4 Suppl):RF6-03.","DOI":"10.1158\/1557-3265.SABCS25-RF6-03"},{"key":"10.1016\/j.ctrv.2026.103218_bb0475","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103218_bb0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-025-00868-y","article-title":"Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling","volume":"12","author":"Sledge","year":"2026","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103218_bb0485","article-title":"Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer","volume":"10","author":"Tarantino","year":"2026","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0490","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.2967\/jnumed.124.267636","article-title":"Whole-body HER2 heterogeneity identified on HER2 PET in HER2-negative, \u2212low, and -positive metastatic breast cancer","volume":"65","author":"Eisses","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2026.103218_bb0495","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1200\/JCO.18.00242","article-title":"National Cancer Institute breast Cancer steering committee working group report on meaningful and appropriate end points for clinical trials in metastatic breast cancer","volume":"36","author":"Seidman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103218_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.106062","article-title":"Progression-free survival 2 (PFS2) as a surrogate endpoint for overall survival (OS) in breast cancer randomized controlled clinical trials","volume":"11","author":"Filis","year":"2026","journal-title":"ESMO Open."},{"key":"10.1016\/j.ctrv.2026.103218_bb0505","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10549-024-07506-4","article-title":"Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records","volume":"209","author":"Cottu","year":"2025","journal-title":"Breast Cancer Res Treat"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:11:55Z","timestamp":1792012315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226001325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":101,"alternative-id":["S0305737226001325"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103218","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing therapies for HER2-positive metastatic breast cancer: Navigating a wealth of treatment options","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103218","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103218"}}